With just-arrived competition in mantle cell lymphoma, Johnson & Johnson’s Imbruvica has snagged reimbursement backing in an important new market. More: NICE flip-flops to back J&J's Imbruvica in mantle cell lymphoma Source: fierce
read moreBristol-Myers Squibb could have yet another approval for its Opdivo-plus-Yervoy combo on the way. The FDA has started a priority review on the two-drug combo as a treatment for kidney cancer, based on data released just three months ago. More: FDA puts
read morePfizer, already laboring to pick up market share with its Remicade biosimilar Inflectra, now has a second FDA-approved copycat. Don’t expect a sales boost from Ixifi, though. Pfizer has no plans to launch it. More: Pfizer weighs 'strategic options' for
read moreTeva’s layoffs and cost cuts are here—and they’re far larger and deeper than reports predicted. The company intends to ax 14,000 jobs, more than one-fourth of its worldwide workforce, while shutting down plants, R&D facilities and offices around the globe.
read moreFrench CDMO Novasep, which has been making clinical supplies for a new-generation antibiotic being developed by U.S.-based Tetraphase Pharmaceuticals, will now start production for a potential commercial launch next year. More: Novasep moves eravacycline API to commercial-scale production Source: fierce
read moreGW Pharmaceuticals has reacquired full ownership of US rights to its cannabinoid medicine Sativex following the termination of a previous license agreement with Otsuka. More: GW regains US rights to Sativex Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals